亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece

作者
Maria Kallieri,Εleftherios Ζervas,Κonstantinos Κatsoulis,Evangelia Fouka,Κonstantinos Porpodis,Κonstantinos Samitas,Andriana Papaioannou,Maria Kipourou,Panagiotis Lyberopoulos,Εleni Gaki,Stylianos K. Vittorakis,Μiltiadis Μarkatos,Katerina Dimakou,Sevasti Ampelioti,Sofia Koukidou,Michail Makris,Maria Ntakoula,Marija Hadji-Mitrova,Spyridon A. Papiris,Νikolaos Tzanakis
标识
DOI:10.1183/13993003.congress-2020.1414
摘要

Introduction: Μepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed one year of therapy with mepolizumab. Material and Method: This study is a prospective multi-centre, non-interventional 2 -year observational study and aims to describe the clinical benefit and safety profile of mepolizumab in patients with severe eosinophilic asthma. Results: Compared to the year preceding the initiation of treatment, the annual rate of exacerbations decreased significantly, from 4.3±2.3 to 1.3±1.8; p <0.0001. 42 patients received maintenance dose of OCS at baseline. From these patients at the end of one year of therapy with mepolizumab 17 patients (40%) had achieved OCS discontinuation. A reduction in the median dose of OCS was also achieved. After 1 year of treatment with mepolizumab the ACT score significantly increased from 16.3±3.7 to 21.2±3.8 (p<0.0001). This marked clinical improvement was paralleled by a significant reduction of blood eosinophil count. All patients showed a considerable improvement of airflow limitation. In respect to Adverse Events (AE) of treatment with mepolizumab, 19 patients (27%) were recorded to have at least one such occurrence during their 1-year treatment. Conclusions: We have shown that in patients with severe eosinophilic asthma, one year of treatment with mepolizumab was safe, resulted in significant reduction of the annual exacerbation rate, reduction (or even discontinuation) of the needed dose of oral corticosteroids, and improvements of asthma control and lung function.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
悦耳破茧完成签到 ,获得积分10
3秒前
3秒前
7秒前
10秒前
11秒前
邓润杰发布了新的文献求助20
16秒前
大胆的纲完成签到,获得积分10
17秒前
万能图书馆的应助被kelite采纳,获得10
19秒前
NexusExplorer的应助被kelite采纳,获得10
20秒前
思源的应助被kelite采纳,获得10
20秒前
斯文败类的应助被kelite采纳,获得10
20秒前
我是老大的应助被kelite采纳,获得10
20秒前
Orange的应助被kelite采纳,获得10
20秒前
顾矜的应助被kelite采纳,获得10
20秒前
乐乐的应助被kelite采纳,获得10
21秒前
顾矜的应助被kelite采纳,获得10
21秒前
大个的应助被kelite采纳,获得10
21秒前
可爱惠完成签到,获得积分10
22秒前
22秒前
852的应助被重要白亦采纳,获得10
23秒前
23秒前
谭豆豆发布了新的文献求助10
28秒前
30秒前
30秒前
34秒前
重要白亦发布了新的文献求助10
35秒前
科研小白发布了新的文献求助10
41秒前
molihuakai的应助被谭豆豆采纳,获得10
42秒前
平常的过客完成签到,获得积分10
42秒前
oliverrrr完成签到,获得积分10
44秒前
隐形的妙松完成签到,获得积分10
45秒前
hotdx完成签到,获得积分10
46秒前
47秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
48秒前
Maestro_S的应助被科研通管家采纳,获得10
48秒前
小蘑菇的应助被科研通管家采纳,获得10
48秒前
50秒前
李爱国的应助被科研小白采纳,获得10
50秒前
abb完成签到,获得积分10
53秒前
Noob_saibot完成签到,获得积分10
54秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21780029
捐赠科研通 7764817
什么是DOI,文献DOI怎么找? 3431496
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476571